Medtronic plc (MDT) has been under a strong bear grip, hence the stock is down -0.97% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.15% in the past 1 week. The 4-week change in the price of the stock is -1.18% and the stock has fallen -0.51% in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.73% and the fifty day Moving Average is 0.24%. Medtronic plc is up 6.54% in the last three month period. Year-to-Date the stock performance stands at 13.72%.
Medtronic plc (MDT) has been rated by 14 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $104 and the lowest price target forecast is $56. The average forecast of all the analysts is $89.39 and the expected standard deviation is $11.4.
Medtronic plc (NYSE:MDT): stock turned positive on Friday. Though the stock opened at $85.62, the bulls momentum made the stock top out at $86.85 level for the day. The stock recorded a low of $85.6 and closed the trading day at $86.6, in the green by 1.42%. The total traded volume for the day was 6,181,557. The stock had closed at $85.39 in the previous days trading.
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.